Bayer AG: Phase III Study of Bayer?s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint
It is intended to present these data as soon as possible at a forthcoming scientific congress as well as to file for market authorization by the end of this year.
This Ad-hoc Statement may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks,
uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These
factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer AG, Investor Relations contacts:
Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)
Ute Menke (+49-214-30-33021)
Posted: September 2011